Navigation Links
Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008
Date:7/29/2008

p> Cash and cash equivalents $673,371 $818,669

Investments - 7,596

Receivables, net 338,142 276,776

Inventory, net 114,479 99,098

Deferred tax assets, net 154,381 176,619

Other current assets 47,782 43,267

Total current assets 1,328,155 1,422,025

PROPERTY AND EQUIPMENT, net 512,449 500,396

GOODWILL 484,029 476,515

INTANGIBLE ASSETS, net 793,066 817,828

DEFERRED TAX ASSETS, net 176,148 141,752

OTHER ASSETS 163,042 147,753

$3,456,889 $3,506,269

CURRENT LIABILITIES:

Current portion of long-term debt $823,131 $1,237,169

Accounts payable 82,265 91,437

Accrued expenses 677,911 677,184

Total current liabilities 1,583,307 2,005,790

LONG-TERM DEBT 202,834 3,788

DEFERRED TAX LIABILITIES, net 74,577 56,540

OTHER LIABILITIES 137,225 138,084

Total liabilities 1,997,943 2,204,202

STOCKHOLDERS' EQUITY:

Common stock, $0.01 par value 708 700

Additional paid-in capital 2,007,582 1,934,965

Treasury stock, at cost (194,782) (158,173)

Accumulated deficit (525,209) (62
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... KY and Manhattan, KS (PRWEB) , ... June ... ... has acquired US PATENT 7736892 B2. Under the terms of the agreement, MediVet ... Umbilical Cord Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as ...
(Date:6/29/2015)... June 29, 2015  AACC, a global scientific ... through laboratory medicine, is pleased to announce that ... Chemistry , has increased to 7.9 in the ... places Clinical Chemistry in the top ... significant influence of the research it publishes on ...
(Date:6/29/2015)... June 29, 2015 According to a ... XNA), by Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other ... Companies, CRO) - Global Forecast to 2020", published by MarketsandMarkets, ... by 2020 from $107.56 Million in 2015, at a CAGR ... ables and 67 F igures spread through ...
(Date:6/29/2015)... , June 29, 2015   For the seventh year ... to assess their overall digital maturity called the ... these companies are not maturing fast enough. While it,s ... in numerous ways overall and customers are increasingly "digital ... of digital customer engagement.  ...
Breaking Biology Technology:MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4
... Key Secondary Endpoints,NEW YORK, March 10 Intra-Cellular Therapies, ... Phase II trial in patients with Sleep Maintenance Insomnia ... increased slow wave sleep and decreased the duration of ... meeting the prespecified primary and key secondary endpoints of ...
... March 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... positive clinical study results for its Bio-Seal(TM) Lung ... Interventional Radiologists Annual Scientific Meeting in San Diego, ... of Bio-Seal in patients undergoing lung biopsy procedures ...
... 9 Former Presidential candidate Gary Bauer on Monday called ... embryonic stem cell research "evidence that ideology is the goal ... a tragedy, as lives will be lost and not saved ... Values made the following statement: "It,s tragic that Barack Obama ...
Cached Biology Technology:Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7Angiotech announces positive results from Bio-Seal(TM) clinical study 2Angiotech announces positive results from Bio-Seal(TM) clinical study 3Angiotech announces positive results from Bio-Seal(TM) clinical study 4Angiotech announces positive results from Bio-Seal(TM) clinical study 5
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical ... use solutions, headquartered in Springville, Utah , ... California corporation with locations in Santa ... Rica ). This acquisition will incorporate MedConx,s ... ATL Technology,s existing facility in Costa Rica ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... A team from the National Institute of Standards ... Guard on a coordinated effort to train emergency first ... securing reliable samples of suspected biothreats. The project, dubbed ... first responders at the state, local and federal levels ...
... in the journal Annals of Botany , Professor Douglas ... in the ground could harvest more carbon from the air, ... levels. In principle, any crops could be treated in ... for the environment. Although the amount of carbon presently ...
... Nobel Prize for nerve growth factor was awarded more than ... use growth factor clinically. University of Pittsburgh Professor Yadong ... factor to regrow blood vessels. His research, which could be ... death in the Western world, is published this week in ...
Cached Biology News:Operation Vigilant Sample: First responder training for suspicious powders 2Crop breeding could 'slash CO2 levels' 2Regrowing blood vessels with a potent molecule 2Regrowing blood vessels with a potent molecule 3Regrowing blood vessels with a potent molecule 4
...
... feature a dual strength adhesive system which facilitates ... The adhesives on either side of the frame ... to the glass has an easy release adhesive ... forms a stronger bond. This means that when ...
... Cultures (ECACC) has been offering training courses ... institutes for over seven years. We offer ... candidates to cell culture and a Level ... areas such as planning and management of ...
... cover slips for in situ hybridization,in ... on glass slides., Constant probe ... not adsorb probes. , Ready-to-use-Hybri-slips do ... , Avoid RNA degradation-Hybri-slips are supplied ...
Biology Products: